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Muscle Relaxants for Nonspecific Low Back Pain:
A Systematic Review Within the Framework of the
Cochrane Collaboration
Maurits W. van Tulder, PhD,*† Tony Touray, MD,* Andrea D. Furlan, MD,‡
Sherra Solway, MSc, BSc (PT),‡ and Lex M. Bouter, PhD*
Study Design. A systematic review of randomized
and/or double-blinded controlled trials.
Summary of Background Data. The use of muscle re-
laxants in the management of nonspecific low back pain
is controversial. It is not clear if they are effective, and
concerns have been raised about the potential adverse
effects involved.
Objectives. The aim of this review was to determine if
muscle relaxants are effective in the treatment of nonspe-
cific low back pain.
Methods. A computer-assisted search of the Cochrane
Library (Issue 2, 2002), MEDLINE (1966 up to October
2001), and EMBASE (1988 up to October 2001) was car-
ried out. These databases were searched using the algo-
rithm recommended by the Cochrane Back Review
Group. References cited in the identified articles and
other relevant literature were screened. Randomized
and/or double-blinded controlled trials, involving patients
diagnosed with nonspecific low back pain, treated with
muscle relaxants as monotherapy or in combination with
other therapeutic methods, were included for review.
Two reviewers independently carried out the method-
ologic quality assessment and data extraction of the tri-
als. The analysis comprised not only a quantitative anal-
ysis (statistical pooling) but also a qualitative analysis
(“best evidence synthesis”). This involved the appraisal
of the strength of evidence for various conclusions using
a rating system based on the quality and outcomes of the
studies included. Evidence was classified as “strong,”
“moderate,” “limited,” “conflicting,” or “no” evidence.
Results. Thirty trials met the inclusion criteria. Twenty-
three trials (77%) were of high quality; 24 trials (80%) were
on acute low back pain. Four trials studied benzodiaz-
epines, 11 nonbenzodiazepines, and 2 antispasticity mus-
cle relaxants in comparison with placebo. Results
showedthat there is strong evidence that any of these
muscle relaxants are more effective than placebo for pa-
tients with acute low back pain on short-term pain relief.
The pooled relative risk for nonbenzodiazepines versus
placebo after 2 to 4 days was 0.80 (95% confidence inter-
val: 0.71 to 0.89) for pain relief and 0.49 (95% confidence
interval: 0.25 to 0.95) for global efficacy. Adverse events,
however, with a relative risk of 1.50 (95% confidence in-
terval: 1.14 to 1.98) were significantly more prevalent in
patients receiving muscle relaxants and especially the
central nervous system adverse effects (relative risk 2.04;
95% confidence interval: 1.23 to 3.37). The various muscle
relaxants were found to be similar in performance.
Conclusions. Muscle relaxants are effective in the
management of nonspecific low back pain, but the ad-
verse effects require that they be used with caution. Trials
are needed that evaluate if muscle relaxants are more
effective than analgesics or nonsteroidal anti-inflamma-
tory drugs. [Key words: systematic review, Cochrane Col-
laboration, effectiveness, muscle relaxants, low back
pain] Spine 2003;28:1978–1992
Muscle relaxants are one of the many treatments cur-
rently employed in the management of nonspecific low
back pain (LBP). Thirty-five percent of patients visiting a
primary care physician for LBP are prescribed muscle
relaxants.1 The term “muscle relaxants” is very broad
and includes a wide range of drugs with different indica-
tions and mechanisms of action. Muscle relaxants can be
divided into two main categories: antispasmodic and an-
tispasticity medications.
Antispasmodics are used to decrease muscle spasm
associated with painful conditions such as LBP. Anti-
spasmodics can be subclassified into benzodiazepines
and nonbenzodiazepines.
Benzodiazepines (e.g., diazepam, tetrazepam) are
used as anxiolytics, sedatives, hypnotics, anticonvul-
sants, and/or skeletal muscle relaxants.2 In general, there
is no evidence that any one benzodiazepine is more ef-
fective than another if adequate dosage is given; how-
ever, pharmacokinetic differences between the drugs may
be important considerations in prescription choice.
Nonbenzodiazepines include a variety of drugs that
can act at the brain stem or spinal cord level.2 The mech-
anisms of action with the central nervous system are still
not completely understood. Cyclobenzaprine is structur-
ally similar to the tricyclic antidepressants; however, it
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has strong side effects such as sedation.3 It is currently
believed that cyclobenzaprine acts in the brain stem
rather than at the spinal cord level. Carisoprodol and
metaxalone have moderate antispasmodic effects and are
mildly sedative. Carisoprodol blocks interneuronal ac-
tivity in the descending reticular formation and spinal
cord. Carisoprodol is metabolized to meprobamate.
Meprobamate was introduced as an antianxiety agent in
1955 and is prescribed primarily to treat anxiety, ten-
sion, and associated muscle spasms. Its onset and dura-
tion of action are similar to the intermediate-acting bar-
biturates; however, therapeutic doses of meprobamate
produce less sedation and toxicity than barbiturates. Ex-
cessive use can result in psychological and physical de-
pendence. Chlorzoxazone acts at the spinal cord and
subcortical levels, inhibiting multisynaptic reflex arcs.
The mechanism of action of methocarbamol in humans
has not been established, but may be due to central ner-
vous system depression. It has no direct action on the
contractile mechanism of striated muscle, the motor end-
plate, or the nerve fiber. Cyclobenzaprine and or-
phenadrine have anticholinergic activity (which is re-
sponsible for some side effects such as dry mouth).
Tolperisone has a lidocaine-like activity and stabilizes
nerve membranes. It blocks in a dose-dependent manner
mono- and polysynaptic reflexes at the spinal level. Tol-
perisone is supposed to mediate muscle relaxation with-
out concomitant sedation or withdrawal phenomena.4
Some antispasmodic drugs (e.g., Tizanidine) have
showed in animal studies that in addition to muscle re-
laxant and antinociceptive effect they have also gastro-
protective effects which may favor the combination of
antispasmodics with nonsteroidal anti-inflammatory
drugs (NSAIDs).5
Antispasticity medications are used to reduce spastic-
ity that interferes with therapy or function, such as in
cerebral palsy, multiple sclerosis, and spinal cord inju-
ries.6 The mechanism of action of the antispasticity drugs
with the peripheral nervous system (e.g., dantrolene so-
dium) is the blockade of the sarcoplasmic reticulum cal-
cium channel. This reduces calcium concentration and
diminishes actin-myosin interaction. Baclofen is a
gamma aminobutyric acid (GABA) derivative with cen-
tral nervous system action. It inhibits transmission at
spinal level and also depresses the central nervous
system.7
The use of muscle relaxants for low back pain contin-
ues to be a source of controversy among physicians,
mainly because of their side effects. In addition to seda-
tion, potential adverse effects include drowsiness, head-
ache, blurred vision, nausea, and vomiting. Potential for
abuse and dependency has also been reported.8 The con-
troversy is evident in the recommendations found in na-
tional clinical guidelines for the management of low back
pain in primary care. Some guidelines recommend mus-
cle relaxants alone or in combination with NSAIDs as
optional, others clearly do not recommended using
them.9 Despite this, 91% of physicians report using mus-
cle relaxants even if they are conditionally discouraged
by guidelines.10
The role of muscle spasm in the pathophysiology of
LBP is also controversial. Low back pain is generally
considered to be the result of a self-perpetuating cycle of
pain and spasm. Some physicians have questioned this
model and thus, the efficacy of muscle relaxants.11 Oth-
ers view muscle spasm as a protective physiologic re-
sponse that should not be inhibited by muscle relax-
ants.12 Muscle spasm secondary to a pathologic lesion in
the lumbosacral region (e.g., facet joints, discs, muscles,
or ligaments) will immobilize the back and therefore
contribute to the healing process.
Controversies surrounding muscle relaxants have re-
sulted in some resistance to their use in patient care.
Studies have been published which suggest a potential
role for muscle relaxants in clinical practice13; however,
there is a lack of good quality research on the clinical
application of these drugs.14
Objectives
The aim of this systematic review was to determine if
muscle relaxants are effective in the treatment of nonspe-
cific LBP. The following comparisons were investigated:
1) Muscle relaxants versus placebo
2) Muscle relaxants versus paracetamol/acetaminophen
3) Muscle relaxants versus NSAIDs
4) Muscle relaxants versus mscle relaxants
5) Muscle relaxants  analgesics/NSAIDs versus pla-
cebo  analgesics/NSAIDs
Methods
Criteria for Considering Studies for This Review
Types of studies. Only randomized controlled trials (RCTs)
and double-blind controlled clinical trials (CCTs) were
included.
Types of Participants. Only trials involving patients diag-
nosed with “nonspecific low back pain” were included. Non-
specific LBP was defined as pain localized between the scapulas
and inferior gluteal folds that may or may not radiate down
towards the knees, for which specific etiologies such as infec-
tions, neoplasms, metastases, osteoporosis, fractures, rheuma-
tological disorders, neurologic disorders, and other relevant
pathologic entities have been ruled out clinically.
Trials involving patients with various musculoskeletal dis-
orders were included if results were presented separately for the
subgroup of LBP patients or if more than 50% of the study
population consisted of LBP patients.
Types of Interventions. The use of muscle relaxants as
monotherapy or in combination with other therapeutic meth-
ods was included. The muscle relaxants that are included in this
review are: benzodiazepines (diazepam and tetrazepam), non-
benzodiazepines antispasmodics (cyclobenzaprine, carisop-
rodol, chlorzoxazone, meprobamate, methocarbamol, metaxa-
lone, orphenadrine, tizanidine and flupirtine), and
antispasticity drugs (baclofen and dantrolene sodium). We ex-
cluded the muscle relaxant chlormezanone (Trancopal) from
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this review because this drug was discontinued worldwide in
1996 by its manufacturer due to confirmed serious and rare
cutaneous reactions (toxic epidermal necrolysis) associated
with this drug.15 We also excluded botulinum toxin because it
is not usually classified as a muscle relaxant.
Types of Outcome Measures. Trials using one or more of
the following outcome measures were included:
● Pain intensity (e.g., visual analogue scale [VAS] or numer-
ical rating scale [NRS]) at rest or during the day
● Global measure (overall improvement, proportion of pa-
tients recovered) assessed by the patient
● Back pain specific functional status (e.g., Roland Disabil-
ity Questionnaire, Oswestry Scale)
● Return to work (return-to-work status, number of days
off work)
● Physiologic outcomes (e.g., muscle spasm, range of mo-
tion, spinal flexibility, Lasegue test, or muscle strength)
● Generic functional status (e.g., SF-36, Nottingham
Health Profile, Sickness Impact Profile)
Search Strategy for Identification of Studies. A computer-
assisted search of the Cochrane Library (Issue 2, 2002), MED-
LINE (up to October 2001), and EMBASE (up to October
2001) was carried out. These databases were searched using the
algorithm recommended in the Cochrane Collaboration Hand-
book16 and the Back Review Group. Pertinent references cited
in the identified articles were also screened as well as references
of other systematic reviews.13,14,17 A language restriction ex-
cluding studies not published in English, Dutch, German, Span-
ish, or Portuguese was applied to the selection process because
the authors were not able to read and understand any other
languages. If possible, studies published in other languages will
be included in a future update of this review.
General Procedure of the Review. The review started with a
literature search. Studies meeting the inclusion criteria were
screened and analyzed for methodologic quality. This was fol-
lowed by the extraction and analysis of the relevant data. The
selection of studies, methodologic quality assessment, and data
extraction were carried out by two independent reviewers.
Nineteen studies that were originally identified in MEDLINE,
EMBASE, and the Cochrane Library were independently as-
sessed by one pair of reviewers (T.T. and M.vT.). Eleven stud-
ies4,5,18–26 identified through reference checking were included
at a later stage and were independently assessed by another pair
of reviewers (M.vT. and S.S.; A.F. and S.S.). Results at each
stage were compared and discrepancies were resolved in a con-
sensus meeting.
Methodologic Quality Assessment. The methodologic
quality of each RCT was assessed using the criteria recom-
mended by the Cochrane Back Review Group.27 The studies
were not blinded for authors, institutions, or the journals in
which the studies were published. A pilot test was conducted
using a trial on NSAIDs for back pain that is not included in the
present systematic review. Only the criteria pertaining to inter-
nal validity were applied:
1) Adequate allocation concealment
2) Adequate method of randomization
3) Similarity of baseline characteristics
4) Blinding of patients
5) Blinding of care provider
6) Equal cointerventions
7) Adequate compliance
8) Identical timing of outcome assessment
9) Blinded outcome assessment
10) Withdrawals and dropouts adequate
11) Intention-to-treat analysis
All items were scored as positive (), negative (), or un-
clear (?). High quality was defined as fulfilling 6 or more of the
11 quality criteria. A sensitivity analysis in which the effect of
variations in the cutoff point distinguishing studies of high and
low methodologic quality was conducted. We did not contact
the authors for additional information because most studies
had been published many years ago with only 7 studies pub-
lished in or after 1990.
Data Extraction. The data extraction was carried out by the
same reviewers who performed the quality assessment using a
standardized data extraction sheet. The studies were not
blinded for authors, institutions, or journals in which the stud-
ies were published. A pilot test was conducted using a trial on
NSAIDs for back pain that is not included in the present sys-
tematic review.
The following data were extracted from the studies:
1) Characteristics of the studies
The sponsors of the study and their contributions as well as
authors’ affiliations.
2) Characteristics of study population
Data pertaining to the sample sizes and gender and age of
the patients in the samples. The diagnosis of the patients was
also noted. A distinction was made between acute/subacute
LBP (duration of symptoms less than 12 weeks) and chronic
LBP (duration of symptoms 12 weeks or more). The pres-
ence or absence of sciatica and muscle spasms was also
recorded.
3) Characteristics of interventions
The muscle relaxants investigated and the reference treat-
ments to which they were compared were noted. Specifi-
cally, the type of muscle relaxant (benzodiazepine, nonben-
zodiazepine antispasmodics, or antispasticity drug), the
doses administered, and the frequency and duration of the
administration of the treatments were registered.
4) Characteristics of outcomes
The outcome parameters used in the various trials and the
performance of the treatments as recorded on these param-
eters was extracted. The performance of the treatments was
regarded positive (in favor of intervention) if the difference
from the control group was statistically significant (P 
0.05). For pain outcomes, we considered pain at rest (first)
and pain during the day (second). With regard to global
improvement, if the authors reported both physician’s and
patient’s opinion, we extracted only the patient’s opinion. If
they reported only the physician’s assessment, then we used
this data. We also assessed whether there was a clinically
important difference of pain outcomes.28,29 We considered
a clinically important difference in VAS to be 16 mm or
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30% decrease. For an 11-point NRS, this was 2 points or
more.
Data Analysis. A quantitative or meta-analysis was con-
ducted if studies provided sufficient data. The results were tab-
ulated and formally tested for homogeneity. If data were sta-
tistically heterogeneous, reasons for heterogeneity were
explored. Data were pooled using the random effects model.
The results were plotted as relative risks (RR) with correspond-
ing 95% confidence intervals (95% CI). All RRs were calcu-
lated so that an RR smaller than 1 indicated a positive effect of
muscle relaxants. For example, an RR of 0.74 (95% CI 0.55–
0.98) means that the chance of “not getting pain relief” is 26%
less in the muscle relaxants group compared to the placebo
group, with a CI of 2% to 45%. The data entered in the meta-
analyses were adversive outcomes, that is, number of patients
with “no pain relief,” “no global improvement,” “no improve-
ment in muscle spasms,” etc. The analyses were performed
separately for drug types (benzodiazepines, nonbenzodiaz-
epines, and antispasticity drugs), for various outcome mea-
sures, and for various follow-up moments.
A qualitative analysis (“best evidence synthesis”) was con-
ducted using a rating system consisting of the following levels
of evidence:
Level 1—strong evidence: generally consistent findings in
multiple high quality trials
Level 2—moderate evidence: generally consistent findings in
multiple low quality trials and/or one high quality trial
Level 3a—limited evidence: only one low quality trial
Level 3b— conflicting evidence: inconsistent findings in
multiple trials
Level 4—no evidence: no RCTs and no double-blind trials
Subgroup analyses were planned for the following
combinations:
a) Low back pain with and without sciatica or muscle
spasms
b) Different doses of muscle relaxants
c) Ambulant versus bed rest patients
d) Injection versus oral therapy
Results
Literature Search and Study Selection
The computer-assisted literature search produced a yield
of 7 references in the Cochrane Library, 25 in MED-
LINE, and 25 in EMBASE. Taking into account 11 arti-
cles that were cross-referenced in the 3 databases, a net
total of 46 articles were found to be potentially eligible.
Further assessment of the articles and application of the
inclusion and exclusion criteria resulted in 19 articles.
Eleven additional studies were identified through refer-
ence checking,4,5,18,26 resulting in a total of 30 studies.
Not all studies included in the systematic review of
cyclobenzaprine for back pain13 were included in the
present review, because some of them had included a
mixed population of patients with various musculoskel-
etal disorders. We only included studies if results were
presented separately for LBP patients or if more than
50% of the study population consisted of LBP patients.
A total of 28 studies30–57 identified in electronic data-
bases or through reference checking were excluded.
The following studies were identified in the compari-
sons investigated (some studies included more than one
comparison, so the total is more than 30):
1) Muscle relaxants versus placebo
1a) Benzodiazepines versus placebo25,58–60
1b) Nonbenzodiazepines versus placebo4,18,19,23,59,61–66
1c) Antispasticity versus placebo67,68
2) Muscle relaxants versus paracetamol/aceta-
minophen (no studies)
3) Muscle relaxants versus NSAIDs (no studies)
4) Musc le re laxants versus muscle re lax-
ants18,20,22,24,59,64,69,70
5) Muscle relaxants  analgesics/NSAIDs versus pla-
cebo  analgesics/NSAIDs5,21,71–74
Other Comparisons
Other studies compared ethoheptazine plus meprobam-
ate plus aspirin versus NSAID (mefenamic acid),75 or-
phenadrine versus phenobarbital,63 orphenadrine plus
paracetamol versus aspirin,76 and diazepam plus parac-
etamol-codeine versus levomepromazine plus paraceta-
mol-codeine.26 These studies are summarized in Table 1,
but not included in the results section because they could
not be classified in one of the predefined comparisons.
Methodologic Quality of Included Studies
The median score for methodologic quality of all the
included studies was 6 with a range of 3 to 9 (Table 2). Using
acutoffpointof6outof11criteria,23of the30studies (77%)
were of high quality.4,5,18–23,25,58,61,62,64–71,73,74,76
The most common methodologic shortcomings in the
studies involved (in order of frequency):
● Inadequate concealment of the drug allocation pro-
cedures (93% scored “negative” or “unclear”)
● Failing to evaluate compliance (83% scored “nega-
tive” or “unclear”)
● Inadequate method of randomization (80% scored
“negative” or “unclear”)
● Nonequivalent cointerventions (60% scored “neg-
ative” or “unclear”)
● Failing to apply intention-to-treat analysis (60%
scored “negative” or “unclear”)
● Dissimilarity of the baseline characteristics (47%
scored “negative” or “unclear”)
● Inadequate dropouts (33% scored “negative” or
“unclear”)
Almost all studies had identical timing of outcome mea-
sures (90%) and had adequately blinded patients (93%),
outcome assessments (93%), and care provider (93%).
Comparison of the scores by the reviewers for each study
demonstrated a reviewer concurrence rate of 73%. The
disagreement in 27% of the scores could be attributed to
subtle differences in interpretation of the criteria. This
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was reflected in the systematic nature of the discrepan-
cies in scoring. Random errors in reading of the articles
and recording of the assessments, as well as ambiguities
in the presentation of information in the articles, also
played a role. All disagreements were resolved in a con-
sensus meeting.
Study Characteristics
Twenty-two studies declared at least one relationship
with the pharmaceutical industry. These relationships
varied from authors affiliated with the pharmaceutical
industry, drugs supplied by the industry, support re-
ceived (in terms of statistical evaluations, medical, scien-
tific, and editorial assistance), and explicit declaration
that the study was conducted with grants from the phar-
maceutical industry or was directly conducted by them.
In eight studies, there was nothing declared with regards
to any relationship with the pharmaceutical industry, but
in some studies, they used the precommercial name of the
muscle relaxant drug, such as DS 103-282 for tizanidine.
Data on sample size, age and gender, type and dura-
tion of symptoms, and setting are summarized in Table
1. Twenty-four studies included patients with acute LBP
and 6 studies chronic LBP.4,24,25,58,59,66 No studies spe-
cifically reported on patients with sciatica. Fourteen
studies explicitly stated that the population to be treated
had to be diagnosed with muscle spasms. However, the
accuracy of this diagnosis was not discussed in any of
these studies.
Eight studies were identified which included benzodi-
azepines,22,25,26,58 – 60,69,73 23 studies nonbenzodiaz-
epines,4,5,18–24,59,61–66,69–72,74–76 and 2 studies anti-
spasticity drugs.67,68
Five studies made use of injection therapy. In one of
these studies, the efficacy of a single intravenous injection
was evaluated,65 whereas in the other four studies, an
intramuscular injection was followed by oral
medication.24,60,73,74
Effectiveness of Muscle Relaxants
Benzodiazepines Versus Placebo. Four studies were iden-
tified, one on acute LBP60 and three on chronic
LBP.25,58,59
Acute Low Back Pain. The one low quality trial on acute
LBP showed that there is limited evidence (1 trial; 50
people) that an intramuscular injection of diazepam fol-
lowed by oral diazepam for 5 days is more effective than
placebo for patients with acute LBP for short-term pain
relief and better overall improvement, but is associated
with substantially more central nervous system side
effects.60
Table 1. Methodological Quality Assessment of Randomized and Double-Blind Controlled Trials on the Effectiveness
of Muscle Relaxants for Nonspecific Low Back Pain
Reference 1 2 3 4 5 6 7 8 9 10 11 Total
Arbus58  ?    ? ?     6
Baptista18   ?         6
Baratta61            6
Basmajian59  ?          4
Berry62  ?    ? ?     7
Berry71  ?    ?      7
Bianchi19 ?     ? ?    ? 6
Borenstein72  ?    ? ?     3
Boyles69       ?     8
Bragstad20 ? ?          7
Casale67  ?          9
Corts Giner21            7
Dapas68  ?          7
Gold63  ?          4
Hennies22 ? ?          7
Hindle64            7
Hingorani73  ?          6
Hingorani76            6
Klinger65  ?         ? 7
Lepisto23  ?     ?     8
Moll60  ?          5
Pipino24 ? ?   ?    ?   5
Pratzel4  ?          7
Rollings70            8
Salzmann25 ? ? ?        ? 6
Sirdalud5  ?     ?   ?  6
Sweetman75  ?          5
Tervo74            6
Weber26   ?   ?  ?    3
Wörz66  ?          6
1) Adequate allocation concealment, 2) Adequate method of randomization, 3) Similarity of baseline characteristics, 4) Blinding of patients, 5) Blinding of care
provider, 6) Equal co-interventions, 7) Adequate compliance, 8) Identical timing of outcome assessment, 9) Blinded outcome assessment, 10) Withdrawals and
drop outs adequate, 11) Intention-to-treat analysis.
  positive;   negative; ?  unclear.
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Table 2. Characteristics of Randomized and Double-blind Controlled Trials on the Effectiveness of Muscle Relaxants
for Nonspecific Low Back Pain
Study Design and participants Interventions Outcomes
Arbus58 Randomized, placebo-controlled,
double-blind trial. Sponsored by
Sanofi. N  50; Male/Female (%): ?
Age: 18–80 years. Diagnosis:
chronic LBP with or without
radiological abnormality.
Placebo responders were excluded.
Setting: outpatient.
(I) Tetrazepam 50 mg t.i.d./10 days.
N  25.
(R) Placebo t.i.d./10 days. N  24.
Mean (SD) pain at baseline, day 7 and day 14 (from 1 to
5): (I) 3.4 (0.82), 2.5 (0.94) and 1.73 (1.31); (R): 3.36
(0.62), 3.1 (0.71) and 2.38 (1.08).
[stat. sign. day 7]
Number of patients with difference in pain scores of at
least 1 point at day 7 and day 14: (I): 4 and 15; (R): 1
and 8. [stat. sign. day 7 and 14]
Number of patients with at least 1.5 points decrease in
muscle spasm (score 1 to 3), at day 7 and day 14: (I):
2 and 11; (R): 0 and 4. [stat. sign. day 7 and 14]
Overall efficacy by physician: (I): 64%, (R): 29.2%.
stat. sign.]
Baptista18 Multicenter, double-blind, placebo
controlled trial. Sponsorship: none
declared. N  267; Male/Female
(%): 35.6/60.4. Age: 17–64 years;
mean  41.7 years. Diagnosis:
painful spasms of paravertebral
muscles (acute LBP). Setting:
outpatient.
(I1) Tizanidine 2 mg t.i.d./8 days.
N  89.
(I2) Tizanidine 4 mg t.i.d./8 days.
N  89.
(R) Placebo t.i.d./8 days. N  89.
No differences in percentage pain at rest, muscle spasm
and daily inactivity at baseline, day 3 and day 7.
Global measure of improvement at day 7: (inefficacious
 somewhat efficacious)/(satisfactory  excellent):
(I): 29/47; (R): 32/43.
Baratta61 Randomized, placebo-controlled,
double-blind trial.
Merck Sharp & Dohme performed
statistical evaluation of data.
N  120; Male/Female (%): 59/41;
Mean age: 36 (21–60).
Diagnosis: Acute LBP. Patients with
moderate to severe degree of
muscle spasm and local pain.
Setting: Primary care.
(I) Cyclobenzaprine 10 mg t.i.d.–
q.i.d./10 days. N  58.
(R) Placebo t.i.d.–q.i.d./10 days.
N  59.
Proportion of patients who showed improvement (2
points): in pain, at days 2–4, 5–7 and 8–12: (I): 21%,
53% and 81%; (R): 0%, 15% and 49% [stat. sign.]
Proportion of patients improved (2 points) in muscle
spasm, at days 2–4, 5–7 and 8–12: (I): 10%, 44% and
72%; (R): 0%, 8% and 39% [stat. sign.] Physicians’
global evaluation (5-point ordinal scale): (I): 23, 18, 10,
7 and 0; (R): 2, 13, 24, 20 and 0. [stat. sign.].
Proportion of patients improved (2 points) in ADL at
days 2–4, 5–7 and 8–12: (I): 21%, 53% and 78%; (R):
2%, 28% and 47%. [significant on days 5–7 and 8–12].
Basmajian59 Randomized, placebo-controlled,
double-blind trial. Supported by
Merck Sharp & Dohme.
N  76; Male/Female (%): ? Mean
age: ?
Diagnosis: Chronic LBP. Muscle
spasm, limitation of motion and
ADL, pain and tenderness on
palpation.
Setting: outpatient.
(I1) Cyclobenzaprine 10 mg t.i.d./14
days.
N  34.
(I2) Diazepam 5 mg t.i.d./14 days.
N  36.
(R) Placebo t.i.d./14 days. N  35.
No measurement of pain, global efficacy or activity of
daily living.
Mean decrease of muscle spasm (1–5 point scale) from
baseline to days 13–18: (I1): 3.2 to 2.2; (I2): 2.9 to 1.9;
(R): 3.2 to 2.1. [no differences among groups]
Berry62 Randomized, placebo-controlled,
double-blind trial. Sandoz Ltd.
supplied medication. TIL (Medical)
Ltd.
Organized and monitored study.
N  112; Male/Female (%): 51/49.
Mean age: 41 (16–69)
Diagnosis: Acute LBP.
Setting: Primary care.
(I) Tizanidine 4 mg t.i.d./7 days.
N  59.
(R) Placebo t.i.d./7 days. N  53.
Pain at night, at rest and on movement. Mean (SD) pain
at rest (diary; 100 mm VAS) at baseline, day 3 and day
7: (I): 51 (29.4), 39 (29.6) and 19 (23.2); (R): 51 (26.9), 34
(27.9) and 19 (22.9) [no differences]. Proportion of
patients improved (4-point scale), on day 3 and 7: (I):
47%, 75% (R): 37%, 63%. [stat. sign. on day 7].
Global efficacy: (I): very helpful at day 3  17%, some
help at day 7  84%; (R): very helpful at day 3  8%
and some help at day 7  44%. [no differences].
Berry71 Randomized, placebo-controlled,
double-blind trial. Sandoz Ltd.
supplied medication; TIL (Medical)
Ltd.
Organized and monitored study.




(I) Tizanidine 4 mg plus ibuprofen
400 mg t.i.d./7 days. N  51.
(R) Placebo plus ibuprofen 400 mg
t.i.d./7 days. N  54.
Mean (SD) change in pain at rest (diary; 100 mm VAS)
from baseline to day 3 and day 7: (I): 18 (25.3) and 29
(43.3); (R): 16 (24.9) and 33 (32.9). [no differences].
Proportion of patients with moderate  severe pain/no
pain  mild pain at rest, on day 3 and day 7: (I): 5/46
and 3/43; (R): 15/39 and 12/40) [stat. sign.]
Global efficacy (% improved) on day 3 and day 7: (I) 76%
and 85%; (R): 67% and 81%. [no statistical testing].
Bianchi19 Randomized, placebo-controlled,
double-blind trial. Merck Sharp &
Dohme provided editorial
assistance.
N  48; Male/Female (%): 54/46.
Mean age: 46 (19–67)
Diagnosis: Acute LBP (75%) or neck
pain (25%). Moderate to severe
muscle spasm.
Setting: Outpatient.
(I) Cyclobenzaprine 10 mg t.i.d.–
q.i.d./14 days. N  24.
(R) Placebo t.i.d.–q.i.d./14 days.
N  24.
Mean spontaneous pain (1–5 point scale) at baseline,
day 7 and day 14: (I): 3.7, 1.3, 1.0 (R): 3.6, 1.9, 1.3 [stat.
sign. On day 7, not day 14].
Mean limitation of daily activities (1 to 5) at baseline, day
7 and day 14: (I): 1.4, 1.0 (R): 2.0, 1.2 [stat. sign. on day
7, not on day 14].
Global improvement on day 4, 7 and 14: complete 
satisfactory/unsatisfactory  worsening: (I): 20/3, 20/2
and 20/0; (R): 9/13, 14/6 and 15/0 [stat. sign. on day 4
and 7, not on day 14].
Borenstein72 Randomized, open-label trial.
Supported by Merck Sharp & Dohme.
N  40; Male/Female (%): 70/30
Mean age: 34.5 (20–57)
Diagnosis: Acute, mild to moderate
LBP.
Setting: outpatient.
(I) Cyclobenzaprine 10 mg/8 hrs/14
days plus naproxen 500 mg
initially, followed by 250 mg/6
hrs/14 days.
N  20.
(R) Placebo plus naproxen 500 mg
initially, followed by 250 mg/6
hrs/14 days. N  20.
Pain (0 to 20 NRS), descriptive pain scale (from 0 to 3),
no. of days to resolution of pain: (I): 8.5, (R): 12.5. [no
differences]
Muscle spasm (0  none to 3  severe). (I): 2.0; (R): 3.0.
[stat. sign.].
Functional capacity (0–3 scale): (I): 9; (R): 15. [no
differences].
Global efficacy (0  poor to 4  excellent). [no
differences].
(Table continues)
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Boyles69 Randomized, double-blind trial.
N  80; Male/Female (%): 48/52
Mean age: 39 (19–65)
Diagnosis: Acute LBP.
Setting: outpatient.
(I1) Carisoprodol 350 mg q.i.d./7
days.
N  40.
(I2) Diazepam 5 mg q.i.d./7 days.
N  40.
Pain (100-mm VAS) day 7—baseline (I): 58 (I2): 48;
muscle stiffness (I): 59 (I2): 42; activity (I): 58 (I2): 41;
overall relief: (I): 75, (I2): 56. [stat. sign. For muscle
stiffness, activity, and relief].
Overall improvement (very good  excellent): (I): 70%,
(I2): 45%.
Bragstad20 Randomized, double-blind trial.
Sponsorship not declared, but most likely
Sandoz Ltd supplied the medication.
N  27; Male/Female (%): ?
Mean age: 37 (21–63)
Diagnosis: Acute LBP and muscle
spasms of disc origin.
Setting: secondary care—hospitalized
(7), ambulant (20).
(I1) Tizanidine 2 mg t.i.d., 7 days.
N  14.
(I2): Chlorzoxazone 500 mg t.i.d., 7
days.
N  13.
Difference (4-point scale) at baseline and day 7 for pain
(I): 2.29, 0.83 (I2): 2.31, 0.73, for muscle tension (I): 2.57,
0.71 (I2): 2.69, 0.44; for limitation of movement (I): 2.0,
1.0 (I2): 2.15, 0.9. [no differences].
Overall effectiveness by patient at end of the trial: excellent/
good (I): 11 (I2): 9; moderate/poor (I): 3 (I2): 3.
Casale67 Randomized, placebo-controlled, double-
blind trial. Medication supplied by
Boots-Formenti Pharmaceuticals.
N  20; Male/Female (%): 75/25; Mean
age: 46.9 (37–58)
Diagnosis: acute episode of chronic LBP.
Setting: secondary care.
(I) Dantrolene sodium 25 mg o.i.d./
4 days, N  10.
(R) Placebo o.i.d./4 days. N  10.
Pain during maximal voluntary movements (% variation
on VAS): (I): 50%; (R): 8.6%. [stat. sign.]
Muscle spasm (5-points) proportion improved on day 3
and 4: (I): 85%, 85%; (R): 10%, 30%.
Pain behavior stat. sign. Better in (I) than (R) on day 4.
Corts Giner21 Placebo-controlled, double-blind trial.
Sponsorship: none declared.
N  50; Male/Female (%): 46/54
Mean age: 50 (range 32–63) in muscle




(I) Tizanidine 4 mg t.i.d. 
paracetamol 500 mg/7 days. N
 26.
(R) Placebo t.i.d.  paracetamol
500 mg/7 days. N  24.
Pain (4-point scale) on movement at baseline, day 3 and
7: (I): 2.0, 1.1, 0.3; (R): 2.0, 1.8, 1.4. Pain at rest: (I): 1.8,
0.6, 0.2; (R): 1.8, 1.2, 1.0; Pain at night: (I): 1.8, 0.3, 0.1;
(R): 1.7, 1.0, 0.8. [stat. Sign.]
Muscle spasm (4-point scale) at baseline, day 3 and day
7: (I): 2.0, 1.1, 0.3; (R): 2.1, 1.7, 1.5. [stat. sign.].
Activity daily living (4-point scale) at baseline, day 3 and
day 7: (I): 2.0, 0.8, 0.5; (R): 1.9, 1.6, 1.2. [stat. sign.].
Global efficacy (1  excellent, 2  good, 3  moderate
and 4  poor) at the end of treatment: (I): 20, 3, 0, 3;
(R): 4, 3, 3, 14.
Dapas68 Randomized, placebo-controlled, double-
blind trial.
Sponsored by Ciba-Geigy.
N  200; Male/Female (%): 48/52
Mean age: 42.2 (17–74)
Diagnosis: Acute LBP; muscle spasm
and functional disability 2 wks of at
least moderate severity.
Setting: outpatient.
(I) Baclofen 10 mg, 1–2 tablets
t.i.d.–q.i.d./10 days. N  100.
(R) Placebo 1–2 tablets t.i.d.–q.i.d./
10 days. N  100.
For group of patients with severe pain at baseline (63
baclofen, 60 placebo):
Local pain (5-point scale) at baseline, day 4 and day 10:
(I): 4.1, 2.6, 2.0 (R): 4.1, 3.0, 2.5 [stat. sign.]
Muscle spasm (5-point scale) at baseline, day 4 and day
10: (I): 3.8, 2.5, 1.5 (R): 3.8, 2.8, 2.0 [stat. sign. on day
10].
Patient’s opinion (5-point scale) at baseline, day 4 and
day 10: (I): 4.0, 2.7, 1.8 (R): 4.0, 3.0, 2.2 [stat. sign.]
Data for patients with moderate pain (N  77) not given.
Authors reported that baclofen was sign. better in
daily activity on day 4. No differences on day 10.
Gold63 Randomized, placebo-controlled, double-
blind trial. Supported by Riker
Laboratories, Inc.
N  60; Male/Female (%): ?
Mean age: ?
Diagnosis: Acute LBP and muscle
spasms.
Setting: outpatient.
(I) Orphenadrine 100 mg b.i.d./7
days. N  20.
(R1) Phenobarbital 32 mg b.i.d./7
days. N  20.
(R2) Placebo b.i.d./7 days. N  20.
Reduced pain at 2 days: (I): 9/20; (R1): 3/20; (R2): 4/20 [(I)
stat. sign. better than (R1) and (R2)].
Overall improvement at 2 days: (I): 7/20; (R1): 3/20; (R2):
0/20. [(I) stat. sign. better than (R2)].
Hennies22 Randomized, double-blind trial.
Sponsorship not declared but most likely
Sandoz Ltd supplied medication.
N  30; Male/Female (%): 33/67
Mean age: 47.5 (25–70)
Diagnosis: Acute spasm of back (80%)
and neck (20%) muscles, actual no. of
weeks of duration unknown).
Setting: ‘ambulant patients’.
(I1) Tizanidine, 4 mg t.i.d., 7 days.
N  15.
(I2) Diazepam 5 mg t.i.d., 7 days.
N  15.
Pain (4-point scale) at baseline, day 3 and day 7:
(I): 2.3, 1.3, 0.6; (R): 2.2, 1.7, 1.1. Number of cases with
pain improvement on day 3 and 7: (I): 13, 13; (R): 8, 11.
[stat. sign. on day 3].
Percentage of pain relief at end of trial: (I): 77.4%, (R):
47.8%.
Patient self-assessment of pain (4-point scale) at baseline,
day 3 and day 7: (I): 2.2, 1.1, 0.5; (R): 2.2, 1.7, 1.0.
Daily activities at baseline and after 7 days: (I): 2.1, 0.4, (R):
2.2, 0.8. Number of cases with improvement of daily
activities on day 3 and 7: (I): 12, 13; (R): 10, 14.
Hindle64 Randomized, placebo-controlled, double-
blind trial.
Medications were provided by Wallace
Pharmaceuticals.
N  48; Male/Female (%): 56/44
Mean age: 38.4 (18–70)
Diagnosis: Acute LBP. Mexican migrant
farm laborers with acute lumbar strain
and spasm.
Setting: outpatient.
(I) Carisoprodol 350 mg q.i.d./4
days. N  16.
(R1) Butabarbital 15 mg q.i.d./4
days. N  16.
(R2) Placebo q.i.d./4 days. N  16.
Note:
The three groups were
significantly different at
baseline on scores of pain,
daily activities, global severity
and patient estimate of pain.
The carisoprodol group showed
more severe complaints than
the other groups.
Pain (100 mm VAS) at baseline, day 2 and day 4: (I): 86.0,
33.0, 15.5; (R1): 75.2, 58.7, 49.1 (R2): 65.5, 58.5, 64.0. [(I)
stat. sign. Better than (R1) and (R2)].
Muscle spasm (4-point scale) at baseline, day 2 and day
4: (I): 3.1, 2.4, 1.8 (R1): 3.1, 2.8, 2.6 (R2): 3.0, 2.9, 2.9. [no
differences].
Interference with daily activities (4-point scale) at
baseline, day 2 and day 4: (I): 3.7, 2.4, 1.8 (R1): 3.3, 2.9,
2.7 (R2): 3.1, 3.1, 3.4. [(I) stat. sign. better than (R2)].
Number of patients with global improvement excellent/
good (I): 12 (R1): 2 (R2): 2. [(I) stat. sign. better than
(R1) and (R2)].
(Table continues)
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Hingorani73 Double-blind, placebo-controlled trial.
Roche Ltd. acknowledged for their “help
and cooperation.”
N  50; Male/Female (%): 80/20
Mean age: ?
Diagnosis: Acute LBP severe enough to
require admission to hospital.
Setting: secondary care. All patients
were hospitalized and treated with
complete bed rest and 8/25 in (I) and
6/25 in (R) received additional therapy.
(I) Diazepam injections: 10 mg IM/
6 hrs/24 hrs. Oral: 2 mg q.i.d./5
days plus calcium aspirin 10 g
t.i.d./5 days. N  25.
(R) Placebo injections: water IM/6
hrs/24 hrs. Oral: placebo q.i.d./5
days plus calcium aspirin 10 g
t.i.d./5 days. N  25.
Subjective results (pain and tenderness), no. of patients
improved, no change and worse at the end of
treatment: (I) 19, 5, 1 (R): 18, 5, 2. [no differences].
Objective results (range of motion, straight leg raising
and neurological signs), number of patients improved,
no change and worse at the end of treatment: (I): 16,
7, 2 (R): 15, 8, 2. [no differences].
Hingorani76 Randomized, placebo-controlled, double-
blind trial. Cooperation and assistance
from Riker Laboratories Inc. is
acknowledged.
N  99; Male/Female (%): 61/39
Mean age: 43.5
Diagnosis: Acute LBP of sufficient
severity to require inpatient treatment.
Setting: secondary care.
(I) Orphenadrine 35 mg 
paracetamol 450 mg 2 tablets
t.i.d./7 days. N  48.
(R) Aspirin 100 mg t.i.d./7 days.
N  50.
Number of patients with improvement in pain (4-point
scale) at the end of the trial: (I): 37 (R): 34 [no
differences].
Klinger65 Randomized, placebo-controlled, double-
blind trial. Four authors were affiliated
with the Clinical Research Department
of Riker Laboratories.
N  80; Male/Female (%): 81/19
Mean age: 33.8 (14–62)
Diagnosis: Acute LBP and muscle
spasms.
Setting: tertiary care.
(I) Orphenadrine 60 mg
intravenously, single dose.
N  40.
(R) Placebo intravenously, single
dose. N  40.
Number of patients with self assessment of pain as
none, slight, moderate or severe (45 min. After
injection): (I): 5, 30, 5, 0 (R): 0, 4, 31, 5.
Physician’s assessment of spasm (% better): (I): 95% (R):
10%. [(I) stat. sign. better than (R)]
Global improvement (%, better): (I): 92% (R): 12% [(I) stat.
sign. Better than (R)].
Lepisto23 Randomized, placebo-controlled, double-
blind trial. Sponsorship: none
declared.
N  30; Male/Female (%): 50/50.
Mean age: 42.5 (18–62) (I) and 40.8 (27–
59) (R)
Diagnosis: moderate to severe acute
spasms due to disk prolapse in




(I): Tizanidine 2 mg, t.i.d., 7 days.
N  15.
(R): Placebo, t.i.d., 7 days. N  15.
Mean back pain (4-point scale) at baseline, days 2, 3, 5
and 7: (I): 2.5, 2.0, 1.7, 1.3, 1.0 (R): 2.6, 2.2, 1.9, 1.4, 1.0.
[no difference].
Mean score of muscle spasm (4-point scale), at baseline,
days 2, 3, 5 and 7. (I): 2.9, 1.9, 1.3, 1.0, 0.7 (R): 2.7, 2.3,
1.8, 1.2, 1.2. [stat. sign. only on day 3].
Patient’s assessment of overall response (excellent,
good, moderate, poor): (I): 6, 6, 2, 1 (R): 2, 4, 7, 2 [no
difference].
Moll60 Randomized, placebo-controlled, double-
blind trial. Sponsorship not declared.
N  68; Male/Female (%): 56/44
Mean age: 45.6 (23–72)
Diagnosis: Acute LBP
Setting: ?
(I) Diazepam IM injection 10 mg (2
ml)  2 tablets t.i.d. for 5 days.
Day 5–10 2 tablets t.i.d. or less
if good response.
N  33.
(R) Placebo IM injection (2 ml) 
2 placebo tablets t.i.d. for 5
days. Day 5–10 2 placebo
tablets t.i.d. or less if good
response. N  35.
Note:
Groups were not similar at
baseline.
Patients’ assessment 1 hr after IM injection, 24 hrs,
between 48–72 hs and either at day 5 or day 10 to 14.
Therapeutic effect at end of treatment period (0  no,
1  moderate, 2  good, 3  very good). Mean (SD)
and number of patients with scores of 2 and 3: (I): 1.8
(1.2) 21; (R): 0.3 (0.8) 6. [(I) stat. sign better than (R)]
Pipino24 Randomized single-blind clinical trial.
Sponsorship: none declared.
N  120; Male/Female (%): 42.5/57.5
Mean age: 54.4 (20–77) (I) and 51.7 (24–
76) (R)
Diagnosis: chronic LBP with muscle
spasm
Setting: secondary care—inpatients and
outpatients.
(I1) Pridinol mesilate 4 mg IM
injection b.i.d.  3 days
followed by 2 mg b.i.d. orally 
4 days. N  60.
(I2) Thiocolchicoside 4 mg IM
injection b.i.d.  3 days
followed by 8 mg b.i.d. orally 
4 days. N  60.
Mean (SD) pain intensity (VAS) at baseline, day 4 and
day 7: (I): 62.8 (10.8); 45.8 (12.4); 30.0 (13.9); (I2) 63.5
(10.8); 46.4 (12.4); 30.1 (15.5). [no differences].
Patient rated global efficacy: (I) 47/60  good & very
good; (I2) 39/60  good & very good.
Pratzel4 Randomized, placebo-controlled, double-
blind trial. One of the authors affiliated
with Strathmann AG.
N  112; Male/Female (%): 78/27
Mean age: 50.8 (I) and 47.8 (R)




(I) Tolperisone 100 mg t.i.d., 21
days.
N  67.
(R) Placebo t.i.d./21 days. N  70.
Clinical global impression of efficacy on day 10 and day
21 (1  very good, 4  ineffective) (I): 2.65, 2.20 (R):
2.85, 2.45. [no differences].
Number of patients with overall assessment of efficacy
by the patient after 21 days: very
good/good/moderate/ineffective: (I): 15, 17, 19, 5; (R): 6,
21, 15, 14. [(I) sign. better than (R)].
Rollings70 Randomized, placebo-controlled, double-
blind trial.
Sponsorship: none declared.
N  78; Male/Female (%): 53/47
Mean age: 42 (19–65)
Diagnosis: Acute LBP of at least
moderate intensity with muscle
spasms of 7 days or less.
Setting: outpatient.
(I1) Carisoprodol 350 mg q.i.d./7
days.
N  39.
(I2) Cyclobenzaprine 10 mg q.i.d./7
days. N  39.
Pain (100 mm VAS) at baseline and day 8: (I): 70, 30; (I2):
74, 28. Muscle spasm: (I): 64, 22; (I2): 67, 25. Activity
impairment: (I): 74, 32; (I2): 76, 26.
Overall improvement (very good to excellent) at end of
treatment: (I): 70%, (I2): 70%. No differences between
groups.
(Table continues)
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Chronic Low Back Pain. The 2 high quality trials on
chronic LBP25,58 showed that there is strong evidence (2
trials; 222 people) that tetrazepam 50 mg 3 times daily is
more effective than placebo for patients with chronic
LBP for short-term pain relief and overall improvement.
The pooled RRs and 95% CIs for pain intensity were
0.82 (0.72–0.94) after 5 to 7 days follow-up and 0.71
(0.54–0.93) after 10 to 14 days. The pooled RR and
95% CI for overall improvement was 0.63 (0.42–0.97)
after 10 to 14 days follow-up. One high quality trial58
showed that there is moderate evidence (1 trial; 50 peo-
ple) that tetrazepam is more effective than placebo for
short-term decrease of muscle spasm. One low quality
trial showed that there is limited evidence (1 trial; 76
people) that there is no difference between diazepam and
placebo for short-term decrease of muscle spasm.59
Nonbenzodiazepines Versus Placebo
Eleven studies were identified, eight on acute
LBP18,19,23,61–65 and three on chronic LBP.4,59,66
Acute Low Back Pain. One high quality study on acute
LBP65 showed that there is moderate evidence (1 trial; 80
people) that a single intravenous injection of 60 mg
orphenadrine is more effective than placebo for imme-
diate relief of pain and muscle spasm for patients with
acute LBP.
Three high quality23,61,62 and 1 low quality trial63
showed that there is strong evidence (4 trials; 294 peo-
ple) that oral nonbenzodiazepines are more effective than
placebo for patients with acute LBP for short-term pain
relief, global efficacy, and improvement of physical out-
comes. The pooled RR and 95% CIs for pain intensity
Table 2. Continued
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Salzmann25 Randomized, placebo-controlled double-
blind trial. Sponsored by Sanofi
Winthrop.
N  152; Male/Female (%): 59/41
Mean age: 44.4 (I) and 46.3 (R)
Diagnosis: chronic LBP without benefit
from physiotherapy.
Setting: secondary care—outpatient.
(I): Tetrazepam 50 mg t.i.d./14 days
plus physiotherapy. N  79.
(R): Placebo t.i.d/14 days plus
physiotherapy. N  73.
Percentage of patients reporting 66.6% reduction of
daytime pain at day 3, 7 and 14: (I): 7.3, 29.1, 45.5; (R):
2.1, 8.3, 27.1. [stat. sign. difference at day 7]. Clinical
global impression (marked, moderate,
slight/unchanged, deteriorated) at baseline, day 3, 7
and 14: (I): 5/50, 39/16, 46/9, 45/8 (R): 1/47, 31/17, 41/7,
39/9 [no differences].
Data only presented for 103 patients in per protocol
analysis.
Sirdalud5 Randomized, placebo-controlled, double-
blind trial. Sponsored by Novartis
Pharma AG, Basel.
N  405; Male/Female (%): 48/52
Mean age: 40
Diagnosis: patients with local pain
syndromes (back, neck or shoulder) of
recent onset and clinically discernible
muscle spasms; 50% low back pain.
Setting: not specified.
(I) Tizanidine 2 mg plus diclofenac
50 mg b.i.d./7 days. N  185.
(R): Placebo plus diclofenac 50 mg
b.i.d./7 days. N  176.
Mean pain at rest (4-point scale) at baseline, day 4 and
day 8: (I): 1.98, 0.89, 0.53 (R): 1.87, 1.21, 0.92. [stat.
sign.].
Mean muscle tension (4-point scale at baseline, day 4
and day 8: (I): 1.98, 0.77, 0.29 (R): 1.99, 1.20, 0.77. [stat.
sign.].
Mean disability score (5-point scale) at baseline, day 4
and day 8: (I): 2.01, 0.98, 0.61 (R): 1.97, 1.27, 0.92. [stat.
sign.]
Overall assessment of efficacy at end of treatment (good/
very good): (I): 72% (R): 58% [stat. sign.]
Sweetman75 Randomized, placebo-controlled, double-
blind trial. Sponsorship: none
declared.
N  122; Male/Female (%): 53/47
Mean age: 41.3 (?)




(I) Meprobamate 150 mg plus
ethoheptazine 75 mg plus
aspirin 250 mg 2 tablets t.i.d./7
days. N  40.
(R) Mefenamic acid 500 mg t.i.d./7
days. N  40.
Number of patients experiencing moderate and severe
pain at baseline, day 1 and day 7: (I): 25/40, 17/40, 8/
41; (R): 27/37, 19/32, 6/39 [no differences].
Pain diary (4-point scale) (25% failed to complete).
Day 0 and day 7: 1.45, 0.8; (R): 1.4, 0.7. [no differences]
Patient’s overall assessment (some and marked
improvement) on day 7: (I2): 22; (R): 24 [no difference].
Tervo74 Randomized, placebo-controlled, double-
blind trial. Sponsorship: none
declared.
N  50; Male/Female (%): 34/66
Mean age: ?
Diagnosis: Acute LBP. 38/50 no previous
episodes. 37/50 acute onset of
symptoms. 16/50 work injury.
Setting: outpatient.
(I) Orphenadrine 60 mg (2 ml) IM
followed by orphenadrine (35
mg)  paracetamol (450 mg) 2
tablets t.i.d., 7 days. N  25.
(R) Saline 2 ml IM followed by
paracetamol (450 mg) 2 tablets
t.i.d., 7 days. N  25.
Mean (SE) duration of disability: (I): 8.6 (0.6) days; (R):
12.9 (1.2) days. [stat. sign.].
Subjective impressions of the treatments: no difference
between groups (15 minutes after injection and in the
first follow-up visit).
Note: Baseline measurements, 15 minutes after injection.
Weber26 Double-blind, controlled clinical trial.
Sponsorship: none declared.
N  78; Male/Female (%): 60/40
Mean age: 46.2 (I) and 47.4 (R)
Diagnosis: Acute lumbago-sciatica and
cervical pain; majority LBP
Setting: Secondary care—hospital.
(I) Diazepam t.i.d (7 mg, 7 mg, 10
mg)/6 days  paralgin Forte
(paracetamol 400 mg, codeine
20 mg, promethazine 5 mg)
t.i.d./3 days, then prn. N  33.
(R) Levomepromazine t.i.d (7.5 mg
 7.5 mg  15 mg) 6 days 
paralgin Forte t.i.d./3 days, then
prn. N  45.
Pain intensity (10-point scale) daily during 6 days.
(I) 21/33 patients with satisfactory effect; mean grade
5.30 (R) 26/45 satisfactory effect; mean grade 5.82. [no
differences].
Wörz66 Randomized, placebo-controlled, double-
blind trial. One author affiliated with
ASTA Medica.






(I) Flupirtin 100 mg q.i.d./7 days.
N  53.
(R) Placebo q.i.d./7 days. N  54.
Reduction in pain intensity by 2 categories (5-point
verbal scale) at day 7: (I): 54.3%; (R): 33.4%. [no
difference].
Reduction in muscle spasm by 2 categories (5-point
verbal scale) at day 7 (I): 47.8%; (R): 33.4%. [no
differences].
Overall assessment by the physician (very good  good 
satisfactory): (I): 84.8%; (R): 54.3%. [(I) better than (R)].
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were 0.80 (0.71–0.89) after 2 to 4 days (4 trials; 294
people) and 0.58 (0.45–0.76) after 5 to 7 days follow-up
(3 trials; 244 people). The pooled RR and 95% CIs for
global efficacy were 0.49 (0.25–0.95) after 2 to 4 days (4
trials; 222 people) and 0.68 (0.41–1.13) after 5 to 7 days
follow-up (4 trials; 323 people). The pooled RR and
95% CIs for physical outcomes were 0.76 (0.66–0.88)
after 2 to 4 days (3 trials; 252 people) and 0.55 (0.40–
0.77) after 5 to 7 days follow-up (3 trials; 251 people).
Of the three high quality trials18,19,64 that could not
be included in the statistical pooling due to insufficient
data, 1 large trial (267 people) reported no differences
after 3 and 7 days in pain relief and global efficacy be-
tween tizanidine and placebo.18 Two small trials (48
people each) reported that oral nonbenzodiazepines are
more effective than placebo regarding pain intensity,
global efficacy, and muscle spasm after 7 and 14 days19
and on pain intensity after 4 days.64 However, in the last
trial, groups were not similar at baseline, which may
have biased the results.
Strong evidence from all 8 trials on acute LBP (724
people) showed that muscle relaxants are associated with
more total adverse effects and central nervous system
adverse effects than placebo, but not with more gastro-
intestinal adverse effects; RRs and 95% CIs were 1.50
(1.14–1.98), 2.04 (1.23–3.37) and 0.95 (0.29–3.19), re-
spectively. The most commonly and consistently re-
ported adverse events involving the central nervous sys-
tem were drowsiness and dizziness . For the
gastrointestinal tract, this was nausea. The incidence of
other adverse events associated with muscle relaxants
was negligible.
Chronic Low Back Pain. One high quality trial66 showed
that there is moderate evidence (1 trial; 107 people) that
flupirtine is more effective than placebo for patients with
chronic LBP for short-term pain relief and overall im-
provement after 7 days, but not for reduction of muscle
spasm. One high quality trial4 showed that there is mod-
erate evidence (1 trial; 112 people) that tolperisone is
more effective than placebo for patients with chronic
LBP for short-term overall improvement after 21 days,
but not for pain relief and reduction of muscle spasm.
The low quality trial59 showed that there is limited evi-
dence (1 trial; 76 people) that there is no difference on
short-term reduction of muscle spasm after 18 days be-
tween cyclobenzaprine and placebo for patients with
chronic LBP. The two high quality trials did not show a
difference in side effects.
Antispasticity Drugs Versus Placebo
Acute Low Back Pain. Two high quality trials67,68
showed that there is strong evidence (2 trials; 220 peo-
ple) that antispasticity muscle relaxants are more effec-
tive than placebo for patients with acute LBP for short-
term pain relief and reduction of muscle spasm after 4
days. One high quality trial68 also showed that there is
moderate evidence that antispasticity muscle relaxants
are more effective than placebo for patients with acute
LBP for short-term pain relief, reduction of muscle
spasm, and overall improvement after 10 days.
Muscle Relaxants Versus Paracetamol/Acetaminophen
No RCTs or double-blind trials were identified.
Muscle Relaxants Versus Nonsteroidal Anti-
Inflammatory Drugs
No RCTs or double-blind trials were identified.
Muscle Relaxants versus Muscle Relaxants
Eight studies were identified, five high quali-
ty20,22,64,69,70 and three low quality trials.18,24,59
Carisoprodol. This muscle relaxant was investigated in
two high quality studies on acute LBP. The first study
compared carisoprodol with diazepam.69 Carisoprodol
was superior in performance on all outcome parameters
measured. Comparison of carisoprodol with cyclobenza-
prine-hydrochloride in the second study revealed no sta-
tistically significant differences between the two
treatments.70
Chlorzoxazone. This muscle relaxant was compared
with tizanidine in one high quality study in a very small
sample of patients (27 people) with degenerative lumbar
disc disease.20 No differences were found between the
treatments.
Cyclobenzaprine-Hydrochloride. Cyclobenzaprine was
compared with diazepam in a low quality trial on
chronic LBP, but no significant differences between the
treatments were identified.59 There was also no signifi-
cant difference between cyclobenzaprine and carisop-
rodol in one high quality study on acute LBP.70
Diazepam. In comparison with carisoprodol, diazepam
was found to be inferior in performance for muscle
spasm, global efficacy, and functional status in a high
quality trial on acute LBP.69 In a very small high quality
trial (30 people) comparing diazepam with tizanidine,
there were no differences in pain, functional status, and
muscle spasm after 7 days.22
Tizanidine. This muscle relaxant was compared with
chlorzoxazone and diazepam in two very small high
quality trials.20,22 Both trials did not find any differences
in pain, functional status, and muscle spasm after 7 days.
Pridinol Mesilate. One low quality trial showed no dif-
ferences between this muscle relaxant and thiocolchico-
side on pain relief and global efficacy.24
Muscle Relaxants  Analgesics/NSAIDs versus
Placebo  Analgesics/NSAIDs
Six studies were identified on acute LBP, five high qual-
ity5,21,71,73,74 and one low quality trial.72 Five trials eval-
uated nonbenzodiazepines and only one trial
benzodiazepines.73
Acute Low Back Pain. Three high quality trials showed
that there is strong evidence (3 trials; 560 people) that
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tizanidine plus analgesics21 or NSAIDs5,71 is more effec-
tive than placebo plus analgesics or NSAIDs for patients
with acute LBP for short-term pain relief and decrease of
muscle spasm after 3 to 4 and 7 to 8 days. The other high
quality trial showed no difference on global efficacy, but
the orphenadrine plus paracetamol group had statisti-
cally significantly fewer disability days than the placebo
plus paracetamol group.74 The low quality trial showed
statistically significantly greater decrease of muscle
spasm for cyclobenzaprine plus NSAIDs after 14 days,
but no differences on pain intensity and global efficacy.72
Data on adverse events from four studies (556 people)
were pooled.5,71,72,74 Using the random effects model,
the RR and 95% CI was 1.34 (0.67–2.67), indicating
that there was no statistically significant difference in
total adverse effects. However, the RRs and 95% CIs for
central nervous system and gastrointestinal adverse ef-
fects were 2.44 (1.05–5.63) and 0.54 (0.26–1.14), re-
spectively, showing that combination therapy was re-
sponsible for significantly more central nervous system
adverse effects.
One high quality trial showed no differences on sub-
jective and objective outcomes between a benzodiaz-
epine (diazepam) plus calcium aspirin versus placebo
plus calcium aspirin.73
Preplanned Subgroup Analyses
Low Back Pain With and Without Sciatica and Muscle
Spasms. No trials specifically addressed sciatica. We could
not perform a subgroup analysis of the studies in which
muscle spasms were identified because the accuracy of these
measurements is not described and because we cannot as-
sume that the trials that did not mention muscle spasm
reflect in reality patients without muscle spasm.
Different Doses of Muscle Relaxants. Various muscle re-
laxants were investigated in multiple studies, but the
studies either included the same doses (for example, all
studies evaluating cyclobenzaprine used a dose of 10 mg
3 times daily) or were found to be too heterogeneous in
terms of control interventions and outcome parameters
to be able to make any comparisons.
Ambulant Patients Versus Bed Rest Patients. Two high
quality studies involved patients prescribed bed rest. One
study compared an antispasticity muscle relaxant (ba-
clofen) with placebo and incorporated bed rest in the
therapeutic regimen.68 In comparison with placebo,
there was significant relief of pain and improvement in
terms of global efficacy. Relief of spasm did not reach
statistical significance. The second study investigated a
benzodiazepine (diazepam) plus calcium aspirin versus
placebo plus calcium aspirin and involved patients
treated with complete bed rest.73 No difference was
found between the two treatments in this trial.
Injection Therapy. Five studies made use of injection
therapy, of which four evaluated an intramuscular injec-
tion followed by oral medication compared with placebo
or another muscle relaxant. No trial compared injection
with oral medication.
The first high quality study made use of an initial
course of diazepam therapy administered intramuscu-
larly at a dose of 10 mg every 6 hours for 24 hours.73
This was followed by a course of oral therapy plus cal-
cium aspirin. No differences were found between the di-
azepam and placebo groups at the end of the trial, and
the effect of the injection therapy was not clear.
The second high quality study found shorter duration of
disability with 60 mg of orphenadrine administered intramus-
cularly followed by oral tablets plus paracetamol compared
with placebo. There was no difference in global efficacy. Drop-
out rate in this trial was high.74
One high quality study using 60 mg of orphenadrine
administered intravenously compared to placebo found
significant relief of pain and spasm 45 minutes after a
single injection.65
One low quality trial showed a better therapeutic ef-
fect with intramuscular diazepam followed by oral tab-
lets compared with placebo, but groups were different at
baseline.60
The other low quality trial showed no differences be-
tween pridinol mesilate and thiocolchicoside intramus-
cular followed by oral tablets.24
Sensitivity Analysis
A best-case analysis was carried out in which internal
validity criteria that were scored as unclear (“?”) were
scored as positive. This obviously increased the number
of high quality studies and resulted in only two studies
still being considered low quality.59,63 This procedure
changed the results of benzodiazepines versus placebo
for acute LBP from limited to moderate evidence, but
had no consequences for any of the other results.
Lowering the threshold distinguishing higher and
lower quality studies from 6 out of 11 criteria to 5 out of
11 criteria changed 3 studies from low to high quali-
ty.24,60,75 This produced the same consequences de-
scribed in the paragraph above, changing the results of
benzodiazepines versus placebo for acute LBP from lim-
ited to moderate evidence.
Raising the threshold from 6 out of 11 to 7 out of 11
criteria consequently decreased the number of high qual-
ity studies; 10 trials with quality score of 6 were consid-
ered low quality in this sensitivity analysis. The evidence
on pain relief and global efficacy for tetrazepam versus
placebo for chronic LBP changed from strong to moderate,
and the moderate evidence on muscle spasm to limited. The
evidence that flupirtine is more effective than placebo for
patients with chronic LBP changed from moderate to lim-
ited. There were no other implications on results.
Discussion
Literature Search and Study Selection
The results of this review must be interpreted against
several potential sources of bias involving the literature
search and selection process. A language restriction was
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applied to the selection process in which studies not pub-
lished in English, Dutch, German, Spanish, or Portu-
guese were not admitted for further review. Although we
acknowledge that systematic reviews should aim at in-
clusion of all relevant trials independent of language,
identifying trials published in any language is difficult,
time consuming, and costly. We will attempt to include
other language trials in a future update of this review. In
addition, no efforts were undertaken to track down and
include the results of unpublished studies. It was noted
that no studies were identified that demonstrated nega-
tive results for muscle relaxants. This suggests the possi-
bility of publication bias. It has been demonstrated that
medication trials with positive outcomes are more likely
to be published.77
Methodologic Quality
Using a cutoff point of 6 out of 11 criteria, 77% of the
included studies were found to be of high quality. A large
proportion of these high quality studies fulfilled six cri-
teria, indicating that there is still room for improvement
in the quality of execution and reporting of trials involv-
ing muscle relaxants. The most common methodologic
flaws involved the concealment of treatment allocation,
compliance, and randomization procedure, which were
only adequate in 2, 4, and 6 of the 30 trials, respectively.
Most authors failed to explicitly specify the method or
person responsible for concealing the treatment alloca-
tion and did not evaluate compliance or failed to explic-
itly report compliance data. Taking into account the type
of side effects associated with muscle relaxants and the
fact that the majority of the studies involved patients
treated outside the controlled environment of a second-
ary care setting (i.e., outpatient or primary care setting),
more attention should have been devoted to compliance.
Compliance gives an indication of the tolerability and
acceptability of these drugs to patients. In many studies,
authors merely stated that the trial was “randomized,”
which does not give the reader confidence that a trial has
been properly randomized or that the randomization
procedure was adequate. Finally, in 13 of the 30 studies
(43%), the baseline status of the patients in the various
trial arms was found not to be similar. Very often this
was the result of authors failing to report information on
relevant prognostic factors that must be equally divided
between study groups to prevent bias. This was also true
of cointerventions. In 18 of the 30 trials (60%), cointer-
ventions were either not avoided or not equally distrib-
uted between study groups, making it difficult to assess
the significance of the trial outcomes. To reduce the im-
pact of these methodologic deficiencies on the quality of
the review, the authors of the various trials could have
been contacted to request missing information and data.
This, however, seemed futile, as many of the studies were
over a decade old, rendering the possibility of locating
the authors and receiving the desired information
unlikely.
Performance of Muscle Relaxants Versus Placebo
The results demonstrate strong evidence for significant
symptomatic relief and overall improvement within a
week of therapy for nonbenzodiazepines for acute LBP.
Regarding benzodiazepines, there was strong evidence
for short-term pain relief and overall improvement with
tetrazepam for chronic LBP. However, tetrazepam is
only available in some European countries and in Mex-
ico. Also, the evidence for benzodiazepines comes from
fewer trials than for nonbenzodiazepines. The evidence
of benzodiazepines for acute and nonbenzodiazepines
for chronic LBP is less convincing.
The results of the review indicate that muscle relax-
ants could be of benefit to patients, reducing the duration
of their discomfort and accelerating recovery. These
findings are consistent with the results of a systematic
review on cyclobenzaprine for back pain,13 which
showed that cyclobenzaprine is more effective than pla-
cebo at the price of greater adverse effects. An exception
was dantrolene sodium,67 one of the antispasticity mus-
cle relaxants identified in the review. In comparison with
placebo, this drug demonstrated more significant relief of
pain and spasm with no side effects at the dose used. The
study by Casale67 involved a very small sample size (n 
20), rendering the applicability of the results uncertain.
Although dantrolene circumvents the central nervous
system and thus avoids the characteristic side effects, it is
associated with severe hepatotoxicity and muscular
weakness.78
Although a positive treatment effect was found for
antispasticity muscle relaxants, for acute LBP the clinical
relevance of this finding for the LBP population is ques-
tionable as these medications are typically prescribed for
neurologic disorders such as cerebral palsy, multiple scle-
rosis, and spinal cord injuries.
Performance of Muscle Relaxants Versus
Muscle Relaxants
The results of the analysis of the various muscle relaxants
identified in this review showed that one high quality
study found carisoprodol to be superior to diazepam.
None of the other muscle relaxants was superior to an-
other. They were all similar in performance adhering to
the characteristic pattern of good efficacy and limited
tolerability.
Muscle Relaxants as Adjunctive Therapy
It has been suggested in the literature that muscle relax-
ants in practice could be more useful as an adjunct to
other therapeutic methods, specifically analgesics/
NSAIDs.79 This was confirmed in this review. There was
strong evidence that combination with analgesics or
NSAIDs improved and accelerated recovery, but at the
cost of increased central nervous system adverse effects.
Adverse Effects
The results indicate that muscle relaxants are associated
with adverse events. Central nervous system events were
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more prevalent in patients on muscle relaxants, with the
most common complaints being drowsiness and dizzi-
ness. These effects were consistently reported with all
benzodiazepines and nonbenzodiazepines reviewed. The
incidence of other central nervous system events was
negligible. For the gastrointestinal events, the difference
with placebo was not significant, with the most common
complaint being nausea. These adverse effects, especially
those involving the central nervous system adverse ef-
fects, indicate that muscle relaxants must be used with
caution. These findings concur with the recommenda-
tions on use of muscle relaxants in the management of
LBP as cited in the United Kingdom, American, and
Dutch guidelines17,80,81 and other guidelines.9
Chlorzoxazone is implicated in serious (including fa-
tal) hepatocellular toxicity; however, this is a rare event.
Another drug, chlormezanone, has been implicated in
the genesis of Stevens-Johnson syndrome and toxic epi-
dermal necrolysis. Rare side effects are rarely seen in
clinical trials with small sample sizes. A case-control
study compared 245 people who were hospitalized be-
cause of these conditions and 1147 patients hospitalized
for other reasons. Data were obtained through surveil-
lance networks in France, Germany, Italy, and Portugal.
Among the 245 cases, 13 (5%) used chlormezanone 1 to
21 days before the index day, whereas only 1 among the
control group used this drug. Based on the findings in this
study, chlormezanone was discontinued in 1996
worldwide.15
Minimally Clinical Important Difference
When evaluating the effectiveness of a treatment inter-
vention, statistical significance is a necessary but insuffi-
cient criterion.28,29 The issue of clinical importance must
also be considered, a concept that adds to the challenge
of interpreting results of trials to guide patient care.28,82
But what constitutes a clinically importance change or
difference in scores in an outcome of interest? For out-
comes such as survival, death, or hospitalization, the
answer may be clear, but for subjective outcomes such as
pain, clinical importance is often difficult to
determine.28,29,83
The concept termed minimally clinical importance
difference (MCID) has varying definitions. They all con-
tain the common idea of being the smallest change or
difference in scores that has been defined in some way as
being important.82 Among other things, the determina-
tion of a MCID is dependent on the nature of scores
compared (e.g., within or between group), population
(e.g., acute or chronic LBP), intervention (e.g., muscle
relaxants vs. placebo or vs. active treatments), and
whose perspective of importance is taken into consider-
ation (e.g., patient or clinician). Attempts to ascertain
MCID values for pain intensity in the LBP population
revealed a paucity of literature. Although not necessarily
generalizable to the population of the current review,
Farrar et al28 suggest that a 2-point or 30% reduction on
an 11-point pain intensity rating scale relates to clinical
importance for individuals with chronic pain, and Gal-
lagher et al84 found the MCID for acute abdominal pain
to be 16 mm on a pain intensity visual analogue scale
(95% CI 13–18 mm). Because of the heterogeneity of
how data were reported, differences in scales used, and
lack of relevant criteria for MCID in the LBP population
and specifically in acute LBP, we were not able to include
the MCID in our results. In the trials we reviewed, most
studies reported pain outcome data as a summary statis-
tic for each group (i.e., mean scores). If the differences in
the scores had been large, the clinical importance may
have been more obvious but because the changes were
often small, it was difficult to determine what should be
considered clinically important. This has to do in part
with the nature of a mean score when considering
whether to apply the results to an individual patient28,84;
for example, if a mean change of 10 mm in pain on a VAS
in a population is required before the treatment can be
considered to produce an important effect, it does not
imply that the same change of 10 mm is clinically impor-
tant for an individual.83 Thus, to facilitate more easily
understandable clinical importance of results of efficacy
trials, we suggest future trials incorporate the recommen-
dation of Farrar et al28 that investigators report the pro-
portion of subjects who observe a clinically important
improvement in the groups being compared.
Conclusions
Implications for Practice
The results of this review illustrate strong evidence that
nonbenzodiazepines are effective for acute LBP. The ev-
idence on benzodiazepines for acute and nonbenzodiaz-
epines for chronic LBP is less convincing. It is unknown if
muscle relaxants are more effective than analgesics or
NSAIDs, because there are no trials that directly com-
pared these drugs. Muscle relaxants must be used with
caution. The mechanism by which they induce their ben-
eficial effects is also responsible for the intractable side
effects associated with the central nervous system
(drowsiness, dizziness). Therefore, it must be left to the
discretion of the physician to weigh the pros and cons,
taking into account the needs and preferences of the in-
dividual patient to determine whether or not a specific
patient is a suitable candidate for a course of muscle
relaxants.
Implications for Research
Large high quality trials are needed that directly compare
muscle relaxants to analgesics or NSAIDs. Another area
of interest is the use of peripherally acting muscle relax-
ants for LBP. These agents could potentially induce the
same beneficial effects as those that act through the cen-
tral nervous system, but without the associated side ef-
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fects. Future studies should focus on reducing the inci-
dence and severity of side effects.
Key Points
● A systematic review of 30 randomized and dou-
ble-blinded controlled trials was performed.
● The effectiveness of muscle relaxants for nonspe-
cific LBP was evaluated.
● Muscle relaxants are effective in the management
of acute and chronic nonspecific LBP, but the ad-
verse effects require that they be used with caution.
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